Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Gemma Medcalf

- PMLiVE

Why diagnostics investments are crucial to win the AMR battle

AMR could take the lives of ten million people a year within three decades

- PMLiVE

Innovative Trials nominates Eloise Moffett as New VP of Commercial

Eloise Moffett joins Innovative Trials as New Vice President of Commercial to drive business growth globally

Innovative Trials

- PMLiVE

UK launches ‘revolutionary’ trial for progressive MS patients

Octopus is assessing whether existing drugs can be used to help slow disease progression

- PMLiVE

Johnson & Johnson offers $8.9bn to resolve all talcum powder lawsuits

The company faces more than 38,000 lawsuits alleging that its talc products cause cancer

- PMLiVE

Outsmarting unpredictability: using scenario planning to keep ahead

Scenario planning is now considered an essential tool to navigate uncertainty with confidence

- PMLiVE

The ever-shifting landscape of health wearables

Back in 2018, we published a whitepaper discussing the growing trend of wearables in healthcare, along with the impact that this could potentially have on both patients and the healthcare...

IGNIFI

- PMLiVE

BioNTech and Duality Biologics partner in deal worth over $1.5bn

The companies will co-develop two antibody-drug conjugates for solid tumours

- PMLiVE

Johnson & Johnson’s strategy to resolve talcum powder lawsuits blocked by US appeals court

The company faces more than 38,000 lawsuits alleging that its talc products contain asbestos

- PMLiVE

Positive results for Sanofi’s haemophilia therapy published in The Lancet

Fitusiran reduced annualised bleeding rates by 90% compared to control arms

Biogen Idec building

Biogen and Eisai’s Alzheimer’s drug associated with positive long-term health outcomes

A simulation model estimated lecanemab to potentially slow the rate of disease progression

- PMLiVE

Mind the gap: are digital health solutions really patient centric?

Is telemedicine beneficial for all healthcare conditions, or could this be a good time for pharma to revisit the patient journey and address any gaps?

- PMLiVE

Cytokinetics to discontinue ALS drug candidate following phase 3 trial failure

The neurodegenerative disease affects approximately 27,000 people in the US

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links